BioAge is pleased to announce the initiation of the STRIDES Phase 2 clinical trial evaluating azelaprag, an oral exercise mimetic, for the treatment of obesity. Azelaprag has the potential to increase weight loss while improving body composition when combined with an incretin drug. The STRIDES trial, conducted in collaboration with Lilly and Lilly Chorus, will evaluate the combination of azelaprag with tirzepatide, with a primary endpoint of weight loss at 24 weeks. This trial represents an important milestone in our mission to develop novel therapies for metabolic diseases by targeting the biology of aging. https://lnkd.in/g_U9C3SN Keep reading for more details about this exciting development: • Enhancing the efficacy of incretin therapy with an oral exercise mimetic: STRIDES aims to show that azelaprag can significantly increase weight loss in patients taking incretin drugs. Azelaprag is an oral, small molecule agonist of the apelin receptor designed to mimic key biological effects of exercise. Beyond weight loss, the STRIDES trial will evaluate whether azelaprag can improve body composition and measures of metabolic health and function. • Synergistic approach to weight management, analogous to diet and exercise: By combining azelaprag, an exercise mimetic, with tirzepatide, which reduces food intake, we aim to create a pharmacological parallel to the diet+exercise foundation of traditional obesity interventions. • Enabling all-oral regimens for healthy weight loss: As an orally available, well tolerated small molecule, azelaprag aligns with patient preferences (77% of patients strongly prefer the convenience of oral meds over injectables). In the future, azelaprag has the potential to be combined with oral incretins currently in development into all-oral regimens for healthy weight loss. • Reaching a key patient demographic, older adults: STRIDES will focus on individuals 55 and older, who represent 35-40% of obese adults in the US, and can be especially vulnerable to the health impacts of obesity. This trial represents a key step in our broader strategy to target the biology of aging to treat metabolic diseases.
BioAge Labs
Biotechnology Research
Richmond, CA 12,969 followers
We are harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases.
About us
BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses >65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.
- Website
-
http://bioagelabs.com/
External link for BioAge Labs
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Richmond, CA
- Type
- Privately Held
- Founded
- 2015
- Specialties
- aging, longevity, and biotechnology
Locations
-
Primary
1445A S 50th St
Richmond, CA 94804, US
Employees at BioAge Labs
Updates
-
Thanks to all who joined us for our fourth Boston longevity biotech networking event, where BioAge and more than a hundred of our friends enjoyed fascinating talks, breathtaking views of the Boston waterfront, and great conversations. Deep gratitude to our speakers Anne-Ulrike Trendelenburg, Executive Director of Novartis DARe in Cambridge, and Omar Abudayyeh and Jonathan Gootenberg from Harvard Medical School; our co-sponsor Hevolution Foundation; and our gracious hosts at Boston Consulting Group (BCG) (thank you Michael Ringel for inviting us, and to your team for helping to make it happen!). We love organizing this series, and as always, we're already looking forward to next time!
-
-
The BioAge podcast, Translating Aging, features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!
“We believe every human has the right to live a longer, healthier life.” The Hevolution Foundation is a global non-profit organization that funds research and entrepreneurship in healthspan science, and has already become a major force in the field. This week on Translating Aging, Hevolution CEO Mehmood Khan tells the story of the foundation’s origins, its mission, and his vision for how the science of aging can revolutionize health care around the world. Translating Aging is produced by BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Episode: https://lnkd.in/g3Jw4tyc (click ‘FOLLOW’ for links to your favorite podcast platform) Podcast: https://lnkd.in/gvF4X-ka
-
-
Starts today at 11 AM PT/ 2 PM ET! Still time to register...
Next week at a webinar hosted by HitGen Inc., our SVP-Research Rusty Montgomery will give a talk describing how BioAge used DNA-encoded library screening to discover novel and potent inhibitors of NLRP3, which we are developing for the treatment of diseases driven by neuroinflammation. "Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery" 📅 Wednesday, July 17, 2024 at 2pm EDT/1pm CDT/11am PDT 👉🏼 Register: https://lnkd.in/gDmCd3yH See you there!
-
-
Next week at a webinar hosted by HitGen Inc., our SVP-Research Rusty Montgomery will give a talk describing how BioAge used DNA-encoded library screening to discover novel and potent inhibitors of NLRP3, which we are developing for the treatment of diseases driven by neuroinflammation. "Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery" 📅 Wednesday, July 17, 2024 at 2pm EDT/1pm CDT/11am PDT 👉🏼 Register: https://lnkd.in/gDmCd3yH See you there!
-
-
At #AspenIdeasHealth last weekend, BioAge CEO Kristen Fortney joined Laura Deming of age1 and Richard Klausner of Altos Labs on a panel that delved into the groundbreaking approaches from longevity science that are redefining the future of human health, including cellular reprogramming and new drugs for metabolic disease. Allison Aubrey from NPR moderated. Many thanks to Laura, Richard, Allison, and the Aspen Ideas:Health team for the fascinating conversation! Full video here: https://lnkd.in/gnhDD8hM
-
-
Full video of the webinar is now available! Thanks to Hanadie, Alex, and Ben for a fascinating conversation about the many ways that AI can catalyze progress in longevity biotech.
Recording and Transcript now available from AFAR’s recent webinar “AI for Longevity Drug Discovery: Breakthroughs and Challenges” Moderated by Kristen Fortney, PhD, of BioAge and featuring Hanadie Yousef, PhD, of Juvena Therapeutics, Alex Zhavoronkov, PhD, of Insilico Medicine, and Ben Blue, PhD, of Ora Biomedical, Inc. Watch here: https://lnkd.in/eynm24Gx
-
-
BioAge is proud to sponsor the next in Longevity Global’s Longevity Dialogues series of . At this event, Ashley Zehnder (co-founder & CEO, Fauna Bio) and Nicholas Hertz, Ph.D (co-founder & CSO, Montara Therapeutics, Inc.) will share their perspectives on the opportunities presented by pharma partnerships in longevity biotech. Tuesday, June 25 • 5:30-7:30 PM MBC BioLabs • 135 Mississippi St, San Francisco, CA 94107 Still time to register! https://lu.ma/g57i0xir
-
-
BioAge Labs reposted this
Today at the American Diabetes Association’s annual meeting — the largest conference in the field — BioAge CMO Paul Rubin, MD presented exciting preclinical data about our lead product candidate: In diet-induced obese mice, addition of the oral apelin receptor agonist azelaprag to an incretin drug regimen increases weight loss and improves muscle function and body composition. DIO mice are a key translational model for studies of obesity and other metabolic diseases. In mid-2024, BioAge plans to initiate a Phase 2 trial in mid-2024 evaluating azelaprag in combination with tirzepatide (Zepbound®) in older adults with obesity. https://lnkd.in/gCBs2A3t
BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs
businesswire.com
-
Today at the American Diabetes Association’s annual meeting — the largest conference in the field — BioAge CMO Paul Rubin, MD presented exciting preclinical data about our lead product candidate: In diet-induced obese mice, addition of the oral apelin receptor agonist azelaprag to an incretin drug regimen increases weight loss and improves muscle function and body composition. DIO mice are a key translational model for studies of obesity and other metabolic diseases. In mid-2024, BioAge plans to initiate a Phase 2 trial in mid-2024 evaluating azelaprag in combination with tirzepatide (Zepbound®) in older adults with obesity. https://lnkd.in/gCBs2A3t
BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs
businesswire.com